Evaluation of a novel transseptal puncture device for use in cardiac procedures requiring left atrial access

Transseptal puncture (TSP) is the first step in percutaneous left-heart interventions including atrial fibrillation ablation, left atrial appendage occlusion, and percutaneous mitral valve repair/replacement. Current TSP techniques remain limited by suboptimal imaging visualization, lack of precise control over puncture sites, and a steep learning curve. The Protaryx transseptal puncture device was designed to address these limitations by incorporating a novel atraumatic highly echogenic deployable and retractable nitinol mesh end effector mounted on an extendable catheter. The key advantages of the Protaryx TSP device are the maneuverability of the extendable catheter and the visibility of the end effector that combine to enable precise targeting of the fossa ovalis during TSP. Here, we provide an overview of challenges with transseptal puncture, an overview of the Protaryx device, and early clinical evidence. This includes results of the 5-patient prospective non-randomized observational first-in-human experience with the Protaryx TSP catheter. This study demonstrated early feasibility and safety, with rapid on-target puncture of the fossa ovalis, zero adverse events, and 100% success of structural heart interventions following TSP. The United States Food and Drug Administration (FDA) approval of the Protaryx device has increased options for interventional cardiologists and electrophysiologists seeking to streamline left-sided structural heart intervention.